Thursday, 8 Oct 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US

SHE: 301211

  • #
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
  • Rare / orphan disease drugs
  • Vaccine
  • Auto-immune
  • Cell-therapy
  • Multi-specific antibodies
  • CVD
  • AstraZeneca
  • Hengrui Pharmaceuticals
  • Diabetes
  • SHA: 600276
CompanyDeals

GeneScience Acquires Global Rights to Megestrol Acetate Oral Suspension from TWi Pharmaceuticals – $100M Deal Transforms Distributor into MAH for Cachexia Therapy

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its controlled subsidiary Changchun GeneScience Pharmaceutical Co., Ltd. — through its wholly‑owned subsidiary GENSCI Singapore Pte. Ltd. —…

October 8, 2026
ApicHope's Oral Small‑Molecule GLP‑1R Agonist APH04935 Wins FDA IND Approval – Once‑Daily Pill Targets Obesity in Competitive Weight Loss Market

ApicHope’s Oral Small‑Molecule GLP‑1R Agonist APH04935 Wins FDA IND Approval – Once‑Daily Pill Targets Obesity in Competitive Weight Loss Market

October 8, 2026
Biocause Heilen Wins NMPA Approval for Ibuprofen Arginine Granules – Enhanced‑Solubility NSAID Enters China's OTC Analgesic Market

Biocause Heilen Wins NMPA Approval for Ibuprofen Arginine Granules – Enhanced‑Solubility NSAID Enters China’s OTC Analgesic Market

October 8, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up